COMBINATORIAL PROTEIN LIBRARY SCREENING BY PERIPLASMIC EXPRESSION

• US 20070099267A1
• Filed: 08/22/2006
• Published: 05/03/2007
• Est. Priority Date: 10/27/2000
• Status: Abandoned Application

• Current Assignee: Barrett Harvey, Brent Iverson, George Georgiou
• Original Assignee: Barrett Harvey, Brent Iverson, George Georgiou
• Inventors: Georgiou, George, Iverson, Brent, Harvey, Barrett
• Application Number:
  US11/466,352
• Publication Number:
  US 20070099267A1
• Time in Patent Office: Days
• US Class Current: 435/69.1
• CPC Class Codes: C07K 2319/034 containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
• CPC Class Codes: C12N 15/1034 Isolating an individual clone by screening libraries
• CPC Class Codes: C12N 15/1037 Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
• CPC Class Codes: C12N 15/1086 Preparation or screening of expression libraries, e.g. reporter assays
• CPC Class Codes: C40B 40/02 Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Abstract

The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in the periplasm of gram negative bacteria and mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the outer surface-expression of ligand fusion proteins employed with phage display.

Claims

1. A method of obtaining a bacterium comprising a nucleic acid sequence encoding a binding polypeptide having specific affinity for a target ligand comprising the steps of:

(a) providing a Gram negative bacterium comprising an inner and an outer membrane and a periplasm, said bacterium expressing a nucleic acid sequence encoding a candidate binding polypeptide, wherein the candidate binding polypeptide is exposed within the periplasm of said bacterium;

(b) contacting the bacterium with a labeled ligand under conditions wherein the labeled ligand is capable of contacting the binding polypeptide; and

(c) selecting said bacterium based on the presence of said labeled ligand bound to said candidate binding polypeptide.

2. The method of claim 1, further defined as a method of obtaining a nucleic acid sequence encoding a binding polypeptide having a specific affinity for a target ligand, the method further comprising the step of:

(d) cloning a nucleic acid sequence encoding said candidate binding polypeptide from said bacterium.

3. The method of claim 1, wherein said nucleic acid sequence is further defined as operably linked to a leader sequence capable of directing the expression of said fusion polypeptide to the outer side of the inner membrane.

4. The method of claim 1, wherein said Gram negative bacterium is an E. coli bacterium.

5. The method of claim 1, wherein step (a) is further defined as comprising providing a population of Gram negative bacteria.

6. The method of claim 1, wherein the candidate binding polypeptide is anchored to the outer side of the inner membrane of said bacterium.

7. The method of claim 5, wherein said population of bacteria is further defined as collectively expressing a plurality of nucleic acid sequences encoding a plurality of candidate binding polypeptides.

8. The method of claim 2, wherein the bacterium is non-viable.

9. The method of claim 2, wherein the bacterium is viable.

10. The method of claim 2, wherein cloning comprises amplification of the nucleic acid sequence.

11. The method of claim 7, wherein said plurality of nucleic acid sequences are further defined as encoding a fusion polypeptide comprising a candidate binding polypeptide and a polypeptide anchored to the to the outer side of the inner membrane of the bacterium.

12. The method of claim 5, wherein said population of bacteria is obtained by a method comprising the steps of:

(a) preparing a plurality of nucleic acid sequences encoding a plurality of fusion polypeptides comprising a candidate binding polypeptide and an inner membrane anchor polypeptide; and

(b) transforming a population of Gram negative bacteria with said DNA inserts.

13. The method of claim 5, wherein said population of Gram negative bacteria is contacted with said labeled ligand.

14. The method of claim 5, wherein selecting in step (c) is further defined as comprising at least two rounds of selecting, wherein a sub-population of bacteria is selected based on the presence of said labeled ligand bound to said candidate binding polypeptide and further wherein the sub-population is subjected to at least one additional selection based on the presence of said labeled ligand bound to said candidate binding polypeptide.

15. The method of claim 14, wherein from about two to six rounds of selecting are carried out.

16. The method of claim 14, wherein selecting is carried out by flow-cytometry or magnetic separation.

17. The method of claim 1, wherein said candidate binding polypeptide is further defined as an antibody or fragment thereof.

18. The method of claim 17, wherein said candidate binding polypeptide is further defined as a scAb, Fab or scFv.

19. The method of claim 1, wherein said candidate binding polypeptide is further defined as a binding protein of at least 40 amino acids other than an antibody.

20. The method of claim 1, wherein said candidate binding polypeptide is further defined as comprising less than 39 amino acids.

21. The method of claim 1, wherein said candidate binding polypeptide is further defined as an enzyme.

22. The method of claim 1, wherein said labeled ligand is selected from the group consisting of a peptide, a polypeptide, an enzyme, a nucleic acid, a small molecule and a synthetic molecule.

23. The method of claim 1, wherein said labeled ligand is further defined as fluorescently labeled.

24. The method of claim 1, wherein said nucleic acid encoding a candidate binding polypeptide if further defined as flanked by known nucleic acid sequences, whereby said nucleic acid is capable of being amplified following said selection.

25. The method of claim 1, further comprising treating said bacterium to increase the permeability of the outer membrane of said bacterium to said labeled ligand.

26. The method of claim 25, wherein treating comprises a method selected from the group consisting of:

treatment with hyperosmotic conditions, treatment with physical stress, infecting the bacterium with a phage, treatment with lysozyme, treatment with EDTA, treatment with a digestive enzyme and treatment with a chemical that disrupts the outer membrane.

27. The method of claim 26, wherein treating comprises a combination of said methods.

28. The method of claim 27, wherein treating comprises treatment with lysozyme and EDTA.

29. The method of claim 25, wherein treating comprises treating the bacterium with a combination of physical, chemical and enzyme disruption of the outer membrane.

30. The method of claim 1, wherein said bacterium comprises a mutation conferring increased permeability of said outer membrane to said labeled ligand.

31. The method of claim 1, further comprising removing the outer membrane of said bacterium.

32. The method of claim 1, wherein said bacterium is grown at a sub-physiological temperature.

33. The method of claim 32, wherein said sub-physiological temperature is about 25°

C.

34. The method of claim 1, further comprising removing labeled ligand not bound to said candidate binding polypeptide.

35. The method of claim 1, further defined as comprising contacting the bacterium with at least two labeled ligands.

36. The method of claim 1, wherein said selecting comprises flow cytometry.

37. The method of claim 1, wherein said selecting comprises magnetic separation.

38. The method of claim 1, wherein said ligand and said candidate binding polypeptide are reversibly bound.

39. The method of claim 6, wherein the polypeptide anchored to the outer side of the inner membrane comprises a transmembrane protein or fragment thereof.

40. The method of claim 6, wherein the polypeptide anchored to the outer side of the inner membrane comprises a sequence selected from the group consisting of:

the first two amino acids encoded by the E. coli NlpA gene, the first six amino acids encoded by the E. coli NlpA gene, the gene III protein of filamentous phage or a fragment thereof, an inner membrane lipoprotein or fragment thereof.

41. The method of claim 6, wherein the polypeptide anchored to the outer side of the inner membrane is anchored via an N- or C-terminus of the polypeptide.

42. The method of claim 40, wherein the sequence is an inner membrane lipoprotein or fragment thereof selected from the group consisting of:

AraH, MglC, MalF, MalG, Mal C, MalD, RbsC, RbsC, ArtM, ArtQ, GliP, ProW, HisM, HisQ, LivH, LivM, LivA, Liv E,Dpp B, DppC, OppB,AmiC, AmiD, BtuC, FhuB, FecC, FecD,FecR, FepD, NikB, NikC, CysT, CysW, UgpA, UgpE, PstA, PstC, PotB, PotC,PotH, PotI, ModB, NosY, PhnM, LacY, SecY, TolC, Dsb,B, DsbD, TonB, TatC, CheY, TraB, Exb D, ExbB and Aas.

43. A method of obtaining a bacteria comprising a nucleic acid sequence encoding at least a first binding polypeptide having specific affinity for a target ligand comprising the steps of:

(a) providing a Gram negative bacterium comprising an inner and an outer membrane and a periplasm, said bacteria expressing a nucleic acid sequence encoding a least a candidate binding polypeptide, wherein the candidate binding polypeptide is exposed within the periplasm of said bacterium;

(b) contacting the bacterium with a fluorescently labeled ligand under conditions wherein the labeled ligand is capable of contacting the binding polypeptide; and

(c) selecting said bacterium for the presence of the fluorescently labeled ligand using FACS.

44. The method of claim 43, further defined as a method of obtaining a nucleic acid sequence encoding a binding polypeptide having a specific affinity for a target ligand, the method further comprising the step of:

(d) cloning a nucleic acid sequence encoding said candidate binding polypeptide from said bacterium.

45. The method of claim 43, further defined as comprising providing a population of Gram negative bacteria.

46. The method of claim 45, wherein said population of bacteria is further defined as collectively expressing a plurality of nucleic acid sequences encoding a plurality of candidate binding polypeptides.

47. The method of claim 43, wherein the candidate binding polypeptide is anchored to the outer side of the inner membrane of said bacterium.